drugset

drugset / Trial / NCT06859762

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

NCT06859762 ↗

Phase 1 Recruiting 220 enrolled MediLink Therapeutics (Suzhou) Co., Ltd.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors

Timeline

Start: 2025-07-02
Primary completion: 2027-07
Completion: 2027-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	YL217	Other / unclassified	—	Intravenous

Indications